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Background: Pediatric oligodendrogliomas are rare and appear to show a different molecular profile from
adult tumors. Some gliomas display allelic losses at 1p/19q in pediatric patients, although less frequently than in adult
patients, but this is rare in tumors with an oligodendroglial component. The molecular basis of this genomic abnormality
is unknown in pediatric gliomas, but it represents a relatively common finding in pediatric oligodendroglioma-like
neoplasms with leptomeningeal dissemination.
Results: Multiplex ligation-dependent probe amplification (MLPA) analysis using SALSA P088-B1 for the analysis of
the 1p/19q allelic constitution in a pediatric anaplastic (oligodendro)-glioma showed homozygous co-deletion for
markers: TNFRSF4 (located at 1p36.33), TP73 (1p36.32), PPAP2B (1pter-p22.1), DPYD (1p21.3), and PDCD5 (19q13.12),
and hemizygous deletion of BAX (19q13.3-q13.4). No sequence changes for R132 and R172 of the IDH1/2 genes
were identified.
Conclusions: The molecular findings in this pediatric anaplastic glioma do not allow for a clearly definitive pathological
diagnosis. However, the findings provide data on a number of 1p/19q genomic regions that, because of homozygotic
deletion, might be the location of genes that are important for the development and clinical evolution of some
malignant gliomas in children.
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According to Hargrave D [1] high grade gliomas in pediatric
oncology generally group grade III and IV tumors with
astrocytic or oligodendroglial nature, and include anaplastic
astrocytomas (grade III), glioblastomas (grade IV) and ana-
plastic tumors (grade III) that have a major oligodendroglial
component, i.e., pure oligodendrogliomas and mixed oligo-
astrocytomas. Although malignant astrocytomas represent* Correspondence: jreyh@salud.madrid.org
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article, unless otherwise stated.approximately 8%-10% of all pediatric CNS tumors,
most arising in the supratentorial region, high-grade
oligodendrogliomas in children are rare [2]. An inci-
dence of 6% has been reported for oligodendroglial
tumors (including pure oligodendrogliomas and mixed
oligo-astrocytomas) in children aged 0–14 years [2]. The
histology of these neoplasms with oligodendroglial
component is classical and has been described as having a
“fried-egg” appearance with “chicken-wire” vasculature.
Anaplastic variants are primarily based on the presence of
mitotic activity, microvascularization and necrosis, while
anaplastic astrocytomas are diffusely infiltrating tumors
with increased cellularity, distinct nuclear atypia andentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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adult malignant gliomas is now well defined for tumors
with either astrocytic or oligodendroglial characteristics.
Both types of gliomas are very complex and genetically
heterogeneous, with multiple alterations in critical pathways,
primarily alterations of MGMT (methylation), IDH1/2
(mutation), 1p/19q co-deletion, EGFR and PI3K pathway
variations, and p53 or Rb pathway mutation [5,6]. Among
the pediatric malignant gliomas, EGFR gene amplification
appears to occur less frequently than in tumors from adult
patients, and only 2% have the EGFRvIII variant. In
contrast, it appears that PDGFRA and PDGFRB are
more commonly affected in high-grade pediatric gliomas
[1,7,8]. Recently, whole genome sequencing in low-grade
pediatric gliomas has identified multiple genetic alterations
involving several genes such as BRAF, RAF1, FGFR1, MYB
and MYBL1 [9,10]. Copy number alteration analysis has
demonstrated gains of chromosomes 7, 8 and 5q and
loss of 1p [10]. Up to 6 significantly recurrent regions
of focal deletion have been identified: 9p21.3 (and the
adjacent region), 6q26, 10q21.3, 8p22 and 13q31.3,
where multiple genes with functions related to cancer
development are located [10]. In this report we describe
the partial concurrent homozygous deletion at 1p/19q in
an anaplastic glioma (or oligodendroglioma) that took
place in a 6-year-old boy. This event might provide
insights on a subgroup of pediatric (oligodendro)-gliomas
with 1p/19q involvement.
Case presentation
Medical history and examination
A 6-year-old boy was admitted to the La Paz Hospital
for complaining of tremors in the left arm. The patient
had a history of occasional holocranial headaches and
vomiting over the last 2 months and was experiencing
thalamic pain. There were no memory or behavioralFigure 1 MRI of pediatric glioma. (A) MRI shows a large right thalamic tchanges or performance impairment, and the examination
revealed no papilloedema. The patient had a postural
tremor (6–8 Hz) in the outstretched left arm, which
was more prominent in the distal muscle groups. The
tremor was slightly accentuated when moving the
arm. The tremors ceased when the limb was at rest
and when the patient was asleep. The patient had no
nystagmus or gait ataxia, and his speech was normal.
His osteo-cutaneous reflexes were slightly enhanced
on the left side, but he had no sensory abnormalities. The
examination revealed a slight left hemiparesis. The patient’s
left hand was closed due to dystonia, and his left foot
presented dystonia when walking.
A brain CT scan revealed obstructive hydrocephalus
caused by a hypo-dense right thalamic and upper brainstem
tumor, which was producing a mass effect on the basal
ganglia and a shift in the lateral ventricle. T1-weighted 3
T-MR imaging showed a large heterogeneous solid, cystic
tumor arising from the right thalamus and extending to
the brainstem. An MR-imaging study performed with
gadolinium (Gd) contrast showed a ring-enhancing
pattern. Diffusion-tensor imaging was conducted to locate
the posterior limb of the internal capsule (PLIC) in the
preoperative MR (Figure 1A). The laterally displaced PLIC
was even more posterior than expected, which made an
anterior approach the most appropriate.
Surgery
The child underwent a right frontal craniotomy, and a
trans-cortical frontal approach to the right lateral
ventricle was performed for a gross total resection (GTR)
of the tumor. This procedure was accomplished using a
micro-neurosurgical technique. At the completion of
the resection, an endoscopic third ventriculostomy was
performed. An intraoperative pathological examination
identified an anaplastic (possibly astrocytic) glioma.umor compressing the third ventricle. (B) MRI control 9 months later.
Figure 2 Histopathological features of the pediatric glioma reported. (A) Microcalcifications. (B) A prominent micro-vascular stroma presenting
branching capillaries with endothelial tumefaction can be observed. (C) Anaplastic aspect with high nuclear to cytoplasmic ratio and mitosis was
present. (D) Intermingled “egg-fried” cells can be observed in a number of anaplastic foci.
Figure 3 Tumor immunoreactivity. (A) GFAP immunoreactivity was variable whereas Synaptophysin was negative. (B) Cytoplasmic
immunoreactivity for Vimentin and CD57 (HNK-1) were positive. (C) Nuclear p53 was positive in 15%-20% of cells. (D) Growth fraction (ki 67) was
approximately 30%.
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Table 1 Summary of run by Coffalyser
Gene Markers P Run1 P Run2 PC Run1 PC Run2
NOTCH2 01p12 0.9 0.82 0.57 0.55
TNFRSF4 01p36 0.32 0.14 0.52 0.49
GNB1 01p36.33 0.88 0.84 0.43 0.45
TNFRSF14 01p36.32 1.17 0.9 0.48 0.48
TP73 01p36.3 0.14 0.11 0.61 0.57
PARK7 01p36.33-p36.12 1 0.82 0.59 0.57
MFN2 01p36.22 1 1.02 1.24 1.3
PTAFR 01p35-p34.3 1.24 1.01 0.57 0.55
FAF1 01p33 1.2 1.01 0.53 0.52
PPAP2B 01pter-p22.1 0.31 0.26 0.59 0.57
CYP2J2 01p31.3-p31.2 1.28 1.04 0.52 0.54
LPHN2 01p31.1 1.16 0.98 0.57 0.53
GTF2B 01p22-p21 1.1 0.89 0.59 0.59
DPYD 01p22 0.21 0.15 0.59 0.54
NRAS 01p13.2 0.83 0.64 0.63 0.57
LMNA 01q22 1.18 0.91 1 1.05
CRB1 01q31.3 0.74 0.4 0.88 0.88
TNNT2 01q32.1 1.03 0.96 0.74 0.73
SMARCA4 19p13.2 1.06 1.08 1.3 1.39
LDLR 19p13.3 1.17 1.02 1.04 1.04
CCNE1 19q12 0.88 0.81 0.57 0.58
PDCD5 19q12-q13.1 0.2 0.19 0.52 0.5
UPK1A 19q13.13 1.14 0.79 0.62 0.58
TGFB1 19q13.1 0.95 0.83 0.53 0.5
PPP1R15A 19q13.2 0.67 0.42 0.6 0.57
BAX 19q13.3-q13.4 0.5 0.36 0.58 0.58
CHMP2A 19q13.43 0.97 0.85 0.54 0.53
Control 02p16 1.16 1.14 1.04 1.07
Control 03p25.3 1.35 1.15 0.88 0.83
Control 03q 1.07 1.02 1.06 1.05
Control 05q22 1.24 1.13 0.86 0.85
Control 08q 0.89 0.66 0.95 1
Control 08q13 1.23 0.98 1 1.01
Control 09q21 1.07 1.08 1.3 1.39
Control 11q23 1.34 1.09 1.05 1
Control 13q14.3 0.99 1 1.22 1.27
Control 14q 0.94 0.91 1 1
Control 14q22 0.99 1.01 1.23 1.28
Control 15q21.1 1 0.98 0.56 0.56
Control 17q11.2 0.88 0.63 0.89 0.92
Control 17q21 0.98 1 1.22 1.27
Genes are named by their official symbol. P correspond to the pediatric
glioma of study and PC to an oligodendroglioma with known 1p/19q
codeletion (positive control). Number are the values obtained by Coffalyser
analysis, normalized with DNA from 4 healthy volunteers (references). Bold
style represents total marker loss and italics Loss of Heterozygosity.
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The patient’s postoperative recovery was uneventful.
There was a dramatic improvement in his symptoms in
the immediate postoperative period with virtual cessation
of the tremors. The initial follow-up using 3 T-MR images
obtained 1 month after the surgery showed a GTR of
the tumor and no hydrocephalus. After the initial
follow-up, the child was treated with radiotherapy and
chemotherapy. An MR image obtained 9 months later
revealed no tumor recurrence, and the patient remained
neurologically intact (Figure 1B). No changes have been
observed after 2 years of follow-up.
Anatomical pathology
Tumor proliferation consisted of round to slightly
elongated and densely packed cells with round or ovoid
hyper-chromatic nuclei and scarce cytoplasm, occasionally
expressed as perinuclear halos but without a characteristic
honeycomb pattern. Micro-calcifications were present but
there was no necrosis (Figure 2A). A prominent micro-
vascular stroma presenting branching capillaries with endo-
thelial tumefaction was observed (Figure 2B). Most tumor
cells had an anaplastic aspect with a high nuclear to cytoplas-
mic ratio, and mitosis were present (Figure 2C). However,
intermingled “fried-egg” cells were observed in a number of
anaplastic foci (Figure 2D). GFAP immunoreactivity was
variable whereas Synaptophysin was negative (Figure 3A).
Cytoplasmic immunoreactivity for Vimentin and CD57
(HNK-1) were positive (Figure 3B), and. nuclear p53 was
positive in 15%-20% of cells (Figure 3C). The growth fraction
(ki 67) was approximately 30% (Figure 3D).
The pathology diagnosis was anaplastic glioma, although
a 1p/19q analysis was suggested to obtain clues as to the
presence of a possible oligodendroglial component. The
unconventional microscopic pattern and the infrequent
presentation of oligodendrogliomas in pediatric patients
[2,3] could, however, justify our generic diagnosis.
Methods
Samples and DNA preparation
Samples and clinical-pathological data were obtained
according to the hospital ethics committee procedures.
DNA was isolated from frozen tumor and peripheral
blood using the Wizard Genomic DNA purification kit
(Promega). DNA from an oligodendroglioma with known
1p/19q loss was used as a positive control, and DNA
from four healthy volunteers were used as references
for multiplex ligation-dependent probe amplification
(MLPA) reactions.
Multiplex ligation-dependent probe amplification
(MLPA) analysis
MLPA is a technique by which up to 45 different sequences
corresponding to specific known genes (or genomic regions)
Figure 4 MLPA electrophoresis peak-area patterns. R: Reference non tumoral DNA. PC: Positive control of an oligodendroglioma with known
1p/19q codeletion (arrows). P: pediatric glioma with homozygous deletion of a number of markers (arrow-heads) and hemizygous deletion of
BAX (arrow). Genes and genomic regions at 1p are coloured in red, at 19q are green, and the other probes are black.
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ase chain reaction (PCR)-based experiment [11]. The
sequences detected can be small (~60 nucleotides),
enabling analysis of fragmented DNA. We used the
MLPA SALSA P088-B1 kit (MRC-Holland, Amsterdam,
Netherlands), which contains 15 1p probes, eight 19q probes,
and 20 control probes specific to other chromosomes,
including three 1q probes and two 19p probes. Information
regarding the probe sequences and ligation sites can be
found at www.mlpa.com. MLPA analysis was performed as
described previously [12,13]. In brief, we used 100 ng for
each normal DNA controls and tumor sample. DNA
denaturation and hybridization of the SALSA probes was
followed by a ligation reaction and PCR. One microliter of
the amplified sample product was analyzed using the ABI
3100 Avant sequencer (Applied Biosystems) using the
ROX-500 Genescan (ABI 401734) as an internal size
standard. Duplicate experiments were performed to
obtain accurate MLPA values (Table 1). Data analysis
was performed with MRC-Coffalyser version 9.4 software
(MRC-Holland, Amsterdam, Netherlands). Successful li-
gation reaction and identification of samples with insuffi-
cient amounts of DNA were verified using MLPA's internal
ligation-independent probes. Normalization for tumor data
(including positive control oligodendroglioma and pediatric
patient sample), was performed on the average of the four
references probes. Single regression for references and
tumor data slope correction was performed. Given that
a value of 1 corresponds to a normal allele constitution,LOH ratio limit was set at <0.67, homozygous loss
at <0.34, and gains at >1.3. Probes were considered
as altered only when duplicated runs corresponded to the
same pattern.
Isocitrate dehydrogenase 1 and 2 (IDH1/2) mutation
analysis
The genomic regions spanning the R132 codon of
IDH1 and R172 of IDH2 genes were amplified and
sequenced with an ABI PRISM 3100 Genetic analyzer and
Sequencing Analysis 5.1.1 software (Applied Biosystem,
Foster City, CA, USA) using the primers and conditions
described previously [14,15].
Results
The study was performed in duplicate and five control
samples were used: one corresponding to a known oligo-
dendroglioma with proven 1p/19q loss (positive control),
and four non-tumoral DNAs (used as references for
MLPA analysis). As shown in Figure 4 and Table 1, an
almost complete absence of signal was identified in a
few markers: TNFRSF4 (located at 1p36.33), TP73
(1p36.32), PPAP2B (1pter-p22), DPYD (1p21.3) and
PDCD5 (19q13.12), suggesting that total loss of these
genomic regions occurred in the pediatric tumor re-
ported herein. In addition, heterozygotic loss of BAX
(19q13.3-q13.4) was present, and no mutations of
IDH1/2 were identified. Probe for ZNF342 presented
problems even in references and therefore, it was excluded
Table 2 Biological process of altered genes identified by MLPA in pediatric glioma and of neighbour genes located in
the critical deleted regions
Gene Biological process Chromosomal region Neighbor genes Biological process
TNFRSF4 Inflammatory and immune response 01p36 TNFRSF18 Apoptosis
TTLL10 Protein polyglycylation
SDF4 UV protection





MEGF6 Calcium ion binding
PPAP2B Blood vessel development 01pter-p22.1 PRKAA2 Protein phosphorylation
C1orf168
DPYD Purine base catabolic process 01p22 PTBP2 mRNA processing
PDCD5 Apoptosis 19q12-q13.1 ANKRD27 Early endosome to late endosome transport
DPY19L3
CEP89
SLC7A9 Protein complex assembly
TDRD12
NUDT19
RGS9BP Negative regulation of signal transduction









Only the most nearby protein-coding genes were selected.
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because pediatric glioma and positive control showed
a value of 0. Finally, the tumor DNA displayed allelic
loss involving the 9q21 control marker, although this
was not numerically confirmed (Table 1).
Discussion and conclusions
Pediatric gliomagenesis seems to follow different molecular
pathways from adults. Concurrent deletion of 1p and 19q is
the hallmark of adult oligodendrogliomas (identified in up
to 80% of tumors) [16-18] and results from an unbalanced
t (1;19) (q10; p10) [19,20]. Assessment of allelic status at 1p
and 19q has been established as a key tool for the diagnosis,
treatment and prognosis of adult oligodendrogliomas,
given that tumors carrying the co-deletion usually have a
more favorable response to conventional chemotherapyagents [21,22]. Similarly, MGMT aberrant promoter
methylation has been proposed as potentially associated
with chemosensitivity and prolonged survival [23,24].
IDH1mutations present in most oligodendrogliomas, most
astrocytic tumors and secondary glioblastomas have been
associated with better overall survival and progression-free
survival [15,25]. Aberrant promoter methylation has
also been described [26] and up to three epigenetic
oligodendroglioma groups with various clinical and bio-
logical features have been identified [27]. These neoplasms
are characterized by inactivating mutations of CIC,
concurrent with IDH sequence changes and 1p/19q
deletions [28]. Oligodendrogliomas are less commonly
present in children (1%-3% of pediatric CNS neoplasms) [3]
and the available molecular data suggest that pediatric gli-
omas display molecular features that are slightly different
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or TP53 mutations and positive for MGMT methylation.
However, 1p/19q concurrent deletion appears rare,
although it is present in oligodendrogliomas from
older children (over 10 years of age) [29-31]. Correct
identification of these molecular changes might be
useful if a similar correlation with prognosis could be
found in pediatric oligodendrogliomas. However no
correlation between 1p/19q deletion and increased
survival has been described in a series of high grade
malignant pediatric gliomas, most of which were classified
as astrocytomas [32]. It is possible that the molecular
implications of losses involving 1p/19q in pediatric glial
tumors (including oligodendroglial tumors) are different
from those in adult cases, i.e., that different genes could
be the targets of these alterations and thus no correlation
with increased survival should be expected. Candidate
genes at 1p/19q have been investigated in the search for
potential targets of that co-deletion, including NOTCH2,
CDKN2C, RAD54, CITED4, CAMTA1, TP73, EMP3 and
PEG3, but no consistent mutation of these genes has been
demonstrated [8,33-35]. The infrequent presentation
of oligodendrogliomas in pediatric patients and the
unconventional microscopic pattern observed in the
case reported herein could justify the generic diagnosis
(anaplastic glioma). However, a number of other micro-
scopic features (capillary network, micro-calcifications,
CD57 positivity) are consistent with the presence of an
oligodendroglioma component. The molecular findings
in this tumor, which demonstrate 1p/19q co-deletion
(including homozygosus deletion of a few markers)
could also support an oligodendroglioma diagnosis,
although these molecular alterations are rare in pediatric
oligodendrogliomas [30]. The absence of IDH1 mutations
also agrees with the data in pediatric gliomas, including
oligodendrogliomas [36,37]. Recent reports have identified
no IDH1 mutations with variable allelic constitutions for
1p/19q (including co-deletion to no loss) in disseminated
oligodendroglial-like leptomeningeal tumors in pediatric
patients [38,39]. However, no apparent leptomeningeal
involvement was evident in the case reported herein.
Another report described an aggressive clinical phenotype
(8-month overall survival) characterizing a pediatric
glioblastoma with an oligodendroglioma component,
displaying neither IDH1/2 mutation nor 1p/19q co-deletion
[40], which was clearly different from the case reported
here. In conclusion, a definitive histopathological diagnosis
could not be clearly established, and the doubt remains
about whether this tumour could be classified as displaying
(or not) a true oligodendroglial component. However, the
identification of homozygous deletion involving a number
of 1p/19q markers provides insights on genomic re-
gions in these chromosome arms, where potential
critical target genes, which could participate in thedevelopment of pediatric (oligodendro) gliomas, might be
located. As shown in Table 2, several genes involved in
interesting biological functions are located in the neigh-
borhood of the homozygous deleted markers in the case
reported here. Functional and/or mutational analyses of
these neighbour genes would provide insights on potential
new regulation pathways, perhaps non-randomly involved
in the development of pediatric gliomas.
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